The emergence of dual-action receptor agonists in the approach of type 2 diabetes and obesity has sparked considerable attention, particularly regarding retatrutide and tirzepatide. While both medications target both https://lorixewx707840.dsiblogger.com/71783015/retatrutide-vs-tirzepatide-a-comparative-analysis